Key facts
- Picterus’s last known valuation is $8.9M (Jan 2025).
- It has raised $4.2M.
- Notable investors include European Innovation Council, European Commission, CVX Ventures, Farvatn Venture, Innovasjon Norge — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Picterus
- ·The full record, as it builds
Funding rounds
No funding rounds for Picterus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Picterus
Developer of a smartphone-based neonatal screening tool designed for early detection of jaundice in newborns. The company's platform utilizes a patented color calibration card and an app that ensures correct camera distance, positioning, and quality before capturing images for analysis, enabling healthcare professionals and caregivers with a safer alternative to visual inspection and supporting timely medical intervention for newborns when they are at risk of jaundice.
- Sector
- Healthcare
- HQ
- Trondheim, Norway
- Founded
- 2015
- Employees
- 29
- Website
- picterus.com/
- Ownership
- Privately Held (backing)
Picterus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Picterus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Picterus in its N-PORT filings yet. We sweep new filings monthly.